FindTrial
Sign In

A prospective, open study of the 0619 tablets combined with HLH-94 therapeutic for the treatment of secondary hemophagocytic syndrome

A prospective, open study of the 0619 tablets combined with HLH-94 therapeutic for the treatment of secondary hemophagocytic syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041716
Enrollment
Unknown
Registered
2021-01-02
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hemophagocytic syndrome

Interventions

study arm: 0619 tablets

Sponsors

Anhui Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) The initial diagnosis was HLH, which met at least 5 of the 8 HLH-2004 criteria; 2) Women who are fertile must have a negative serum pregnancy test at screening or before the first dose, and use an approved effective contraceptive method throughout the study period and 28 days after the end or termination of the study. Lactating women should stop breastfeeding.

Exclusion criteria

Exclusion criteria: 1) HLH family history; 2) Patients with recurrent onset since childhood or have ever been diagnosed with HLH; 3) Pregnancy-related secondary HLH; 4) Combined with central nervous system lesions.

Design outcomes

Primary

MeasureTime frame
sCD25;ferritin;complete blood cell count;triglyceride;Hemophagocytosis;—

Countries

China

Contacts

Public ContactLi Zhou

Anhui Provincial Hospital

zhouli-324@163.com+86 17756071226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026